Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Canaccord Genuity, 'would not be surprised if ACAD decides to not pursue a sNDA in NSS'
Tweet Send to a Friend
(Updated - March 12, 2024 10:01 AM EDT)
Canaccord Genuity analyst Sumant Kulkami lowered the price target on Acadia ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord Genuity analyst Sumant Kulkami lowered the price target on Acadia ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
